MA46625B1 - Inhibiteurs de lsd1 et leurs utilisations médicales - Google Patents
Inhibiteurs de lsd1 et leurs utilisations médicalesInfo
- Publication number
- MA46625B1 MA46625B1 MA46625A MA46625A MA46625B1 MA 46625 B1 MA46625 B1 MA 46625B1 MA 46625 A MA46625 A MA 46625A MA 46625 A MA46625 A MA 46625A MA 46625 B1 MA46625 B1 MA 46625B1
- Authority
- MA
- Morocco
- Prior art keywords
- medical uses
- lsd1
- lsd1 inhibitors
- diseases
- formula
- Prior art date
Links
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 101100334370 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fas2 gene Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000001575 pathological effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
L'invention concerne de nouveaux composés de formule (i ou ia') et leurs sels pharmaceutiquement acceptables, qui sont utiles pour le traitement de divers troubles, maladies ou états pathologiques, associés à lsd1. L'invention concerne également des compositions pharmaceutiques comprenant les nouveaux composés de formule (i ou ia'), leurs sels pharmaceutiquement acceptables, et leurs procédés d'utilisation dans le traitement d'un ou de plusieurs troubles, maladies ou états pathologiques, associés à lsd1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413162P | 2016-10-26 | 2016-10-26 | |
| PCT/US2017/058405 WO2018081343A1 (fr) | 2016-10-26 | 2017-10-26 | Inhibiteurs de lsd1 et leurs utilisations médicales |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46625A MA46625A (fr) | 2019-09-04 |
| MA46625B1 true MA46625B1 (fr) | 2023-11-30 |
Family
ID=65351698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46625A MA46625B1 (fr) | 2016-10-26 | 2017-10-26 | Inhibiteurs de lsd1 et leurs utilisations médicales |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR109887A1 (fr) |
| MA (1) | MA46625B1 (fr) |
-
2017
- 2017-10-26 MA MA46625A patent/MA46625B1/fr unknown
- 2017-10-26 AR ARP170102971A patent/AR109887A1/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| MA46625A (fr) | 2019-09-04 |
| AR109887A1 (es) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA64509B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA64121B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA57825B1 (fr) | Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques | |
| MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
| MA47043B1 (fr) | Composés indole carboxamides utiles comme inhibiteurs de kinase | |
| EA202092490A1 (ru) | Модуляторы метилмодифицирующих ферментов, композиции и их применения | |
| MA47079B1 (fr) | Composés amino-triazolopyidines et leur utilisation pour traiter le cancer | |
| MA41179A (fr) | Composés inhibiteurs de parg | |
| TN2019000099A1 (fr) | Anticorps anti-lag-3 et compositions | |
| MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
| MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA47301B1 (fr) | Inhibiteurs sélectifs de jak1 | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA54386B1 (fr) | Modulateurs de trex1 | |
| MA50013B1 (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton | |
| MA46229A (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA38425B1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
| NZ759295A (en) | 5-5 fused rings as c5a inhibitors | |
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| WO2019032528A8 (fr) | Inhibiteurs bicycliques d'histone désacétylase | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine |